T&R Biofab
T&R Biofab is a KOSDAQ-listed Korean regenerative medicine company that uses proprietary 3D bioprinting, ECM biomaterials, and hiPSC cell processing to manufacture patient-specific implants, biosurgical wound-care and hemostatic products, and research bioprinters sold to hospitals, distributors, and academic labs worldwide.
- Company typePublic
- Founded2013
- HeadquartersSiheungodong, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What T&R Biofab does
T&R Biofab (KOSDAQ: 246710, founded March 2013 in Siheung-si, South Korea) is a publicly traded regenerative medicine company that builds a vertically integrated 3D bioprinting platform spanning hardware, biomaterials, and cell processing. Its core technology stack includes the customizable 3DX Printer (up to 6 print heads, ±1μm resolution, polymer and hydrogel co-printing), proprietary preset extrusion multi-material printing, EER-based VdECM/SdECM biomaterials with 50-60% elastin content, and hiPSC-derived cell banking and processing. The product portfolio spans three primary lines: 3D-printed medical devices (TnR PSI Plus, TnR CFI, TnR Mesh, Nasal Mesh, nerve regeneration conduit) for craniomaxillofacial reconstruction; biosurgical solutions (Reproderm-gel, ADM products Reproderm/Reproderm Plus/SSenderm/Antira, powder and matrix hemostatic agents, PU foam dressings); and research-use tools (deCelluid bioink, TnR Scaffold) sold to academic and pharma customers.
The company monetizes through a hybrid model: exclusive B2B medical device distribution via B.Braun Korea (TnR CFI since 2021) and Johnson & Johnson Medical Korea (TnR PSI Plus since 2023, Asia-Pacific scope), direct sales of 3DX Printer systems to universities (POSTECH, Seoul National University, Georgia Tech), and through acquired subsidiary Blispharm (100% acquired December 2024) for cosmeceutical OEM including HA mask packs, PDRN serums, and melting films distributed via QVC Japan, domestic home shopping, and Dr. Ellie brand collaboration. Revenue mechanics combine one-time implant sales per procedure, capital equipment sales to research institutions, and higher-velocity consumer SKUs. Customer segments include university hospitals and surgical centers (primary), medical device distributors and healthcare procurement channels, pharmaceutical and cosmetics companies using organoid models for animal-test-free screening, academic and research institutions, and cosmetics brands. The company projects consolidated 2025 revenue of 300B KRW and operates with 51-100 employees across Siheung headquarters, Pangyo R&D Center, and Seoul (Sinsa) sales office. Regulatory positioning is anchored by 17,000+ TnR CFI procedures with zero adverse events, MFDS Class 4 device approvals, GMP and ISO 13485/9001 certifications, and an FDA 510(k) submission filed June 2025.
T&R Biofab firmographics
Firmographics- Name
- T&R Biofab
- Legal name
- (주)티앤알바이오팹 (T&R Biofab Co., Ltd.)
- Website
- https://tnrbiofab.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- T&R Biofab is a KOSDAQ-listed Korean regenerative medicine company that uses proprietary 3D bioprinting, ECM biomaterials, and hiPSC cell processing to manufacture patient-specific implants, biosurgical wound-care and hemostatic products, and research bioprinters sold to hospitals, distributors, and academic labs worldwide.
- Ownership category
- akta.pro rank
T&R Biofab industry classification
Industry- Product category
- 3D Bioprinting & Regenerative Medicine Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- 3D Bioprinting & Biofabrication (HLAAAGAC)
- akta.pro secondary industries
- Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB), Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
Keywords
Where T&R Biofab is headquartered
LocationHeadquarters
- HQ city
- Siheungodong
- HQ country
- South Korea
- HQ region
- Asia
Offices3 records
Markets served
T&R Biofab business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- 3D-Printed Medical Devices: Sale of FDA/MFDS-approved 3D-printed implantable medical devices including patient-specific implants (PSI Plus), craniofacial implants (CFI), orbital and nasal mesh products, and nerve regeneration conduits. Revenue is one-time per procedure/implant, with recurring volume driven by hospital adoption and surgical volume. Distributed exclusively through B.Braun Korea and Johnson & Johnson Medical Korea.
- 3D Bioprinter and Platform Sales (3DX Printer): Sale and installation of 3DX Printer systems to research institutions (university labs, hospital research centers). Includes hardware customization, software licensing, and technical support. One-time capital equipment sale model. Supplied to POSTECH, Seoul National University, Seoul St. Mary's Hospital, and Georgia Tech.
- Biosurgical Solutions (Wound Care & Hemostats): Sale of VdECM-based wound dressings (Reproderm-gel), PU foam bandages (Reprofoam, Bonofoam), antibiotic-containing wound dressings, ADM products (Reproderm Plus, SSenderm, Antira), and powder/matrix-type hemostatic compounds. Both hospital-direct supply and export channels. Pursuing import substitution in ~2,700B KRW domestic hemostat market.
- Functional Cosmeceuticals & OEM: Revenue from K-beauty functional cosmetic products including melting HA mask packs, HA films, and PDRN serums. Manufactured via acquired subsidiary Blispharm (100% acquired Dec 2024) and sold through QVC Japan, domestic home shopping, and export contracts. Collaborations with Dr. Ellie Byun's global beauty brand. Estimated to contribute 30%+ of projected 300B KRW revenue in 2025.
- hiPSC-Based Cell Therapy & Cell Banking: Revenue from commercial cell bank products derived from 50 FDA-compliant human donors (skin, blood, adipose tissue). Sales of induced pluripotent stem cell-derived cardiomyocytes (iPSC licenses from Academia Japan, licensed 2020). Future revenue anticipated from GMP-grade clinical stem cell banking services and proprietary cell therapy pipeline.
- Bioink and Biomaterial Reagents: Sale of deCelluid™ bioink and research-grade TnR Scaffold products to academic and industrial research customers. Recurring revenue from reagent and consumable supplies to research institutions operating 3DX Printer systems.
Go-to-market motion3 records
Distribution channels6 records
Marketing channels6 records
T&R Biofab product offering
Product offeringCore offering
T&R Biofab develops and manufactures 3D-bioprinted medical devices, biomaterials, and bioprinting platforms for regenerative medicine. Its portfolio includes patient-specific craniofacial implants (TnR PSI Plus, CFI, Mesh, Nasal Mesh), VdECM-based biosurgical wound-care solutions (Reproderm-gel and the ADM product line), the 3DX bioprinting system, and the deCelluid bioink, sold to hospitals, medical-device distributors, and research institutions.
Product overview
T&R Biofab operates as a regenerative medicine company offering a platform-plus-products architecture built around its core 3D bioprinting technology. Its flagship product is the 3DX Printer — a customizable 3D bioprinting system for fabricating artificial tissues and organs — which underpins both clinical-grade medical devices and research products. The medical device portfolio includes Patient-Specific Implants (PSI Plus/VeraPor PSI Plus, TnR CFI, TnR Mesh/Mesh Plus, Nasal Mesh) for craniomaxillofacial and orthopedic reconstruction, all manufactured from biodegradable PCL and β-TCP composites via 3D bioprinting. The biosurgical solutions line includes Reproderm-gel (topical hydrogel wound dressing with VdECM), ADM products (Reproderm Plus/Reproderm/SSenderm/Antira), and complex hemostatic agents (powder and matrix types) targeting the domestic hemostatic market. R&D pipeline products include nerve regeneration conduits, drug-delivery hydrogels, and organoid models (artificial skin, artificial liver). The company also commercializes deCelluid™ bioink for research use and, following the acquisition of BlissPack, expanded into functional cosmetics (HA-based products).
Differentiator
Problem solved
Functional benefit
Brands
- TnR PSI Plus / T&R PSI Plus: Patient-specific 3D-printed biodegradable implant for craniomaxillofacial reconstruction
- 3DX Printer
- Reproderm-gel
- Reproderm / REPRODERM
- Reproderm Plus / REPRODERM PLUS
- SSENDERM / 쎈덤
- ANTIRA / 안티라
- TnR Mesh / TnR Mesh Plus
- Nasal Mesh / 티앤알나잘메쉬
- TnR CFI (CranioFacial Implant)
- Nerve Regeneration Conduit
- OS inject
- Matrix Type Hemostatic Agent
- Powder Type Hemostatic Agent
- Reprofoam / Reprofoam Band
- Bonofoam / 보노폼
- deCelluid™
- TnR Scaffold
Products and services
- TnR PSI Plus (VeraPor PSI Plus)
Quantifiable outcome
- 17,000+ skull implant procedures completed with zero adverse events reported (as of June 2025)
- +4 more outcomes
Companies that use T&R Biofab
Customer profileNamed customers11 records
Segments5 records
Ideal customer profiles5 records
T&R Biofab technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
T&R Biofab partnerships and signals
Strategic signalPartnerships
20 partnerships are on record, tiered minor and core.
- UNIST / Seoul Asan Hospital / et al.minorKorean research consortium including UNIST, Seoul Asan Hospital, and T&R Biofab developing patient-customized tumor organoids for personalized medicine applications.
- EpiBioTech (에피바이오텍)minorMOU signed June 2021 for joint development of hair loss treatment products combining T&R Biofab's biomaterial technology with EpiBioTech's research.
- Blispharm (블리스팩)core100% acquisition of Blispharm completed December 2024. Blispharm is a cosmeceutical OEM specialist with recognized production capabilities. Enables T&R Biofab's entry into functional cosmetics manufacturing and K-beauty global market with products including HA films, PDRN serums, and melting mask packs.
- Hualun Pharmaceutical Commercial Group (화룬의약상업그룹유한회사)coreStrategic partnership signed November 8, 2024 at CIIE Shanghai for China market. Joint product development and manufacturing for Chinese market demand. Hualun is a healthcare subsidiary of Chinese state-owned enterprise Hualun Group, partnering with global companies including J&J, Pfizer, Novo Nordisk, and Integra.
- CoseMAX BT Inc. (코스맥스 비티아이)minorJoint research partner for development of 3D bioprinted full-thickness skin model with rete ridge structure. Research published in International Journal of Bioprinting 2024.
- Hwarang Cosmetics (에삐오)minorSupply contract signed with Korean cosmeceutical company 에삐오 (brand: Bonotox) for Melting HA cosmetic mask pack. First supply contract for T&R Biofab's functional cosmeceutical products.
- Dr. Ellie (Ellie Byun)minorCollaboration with US celebrity and beauty entrepreneur Dr. Ellie Byun for global marketing and sales of T&R Biofab's functional cosmeceutical products under her dr.ellie brand.
- Johnson & Johnson Medical Korea (한국존슨앤드존슨메디칼)coreExclusive supply contract for TnR PSI Plus (patient-specific 3D-printed implants) signed February 2023. Johnson & Johnson distributes the products across Asia-Pacific and Oceania markets. This is a flagship distribution partnership for T&R Biofab's highest-profile medical device product line.
- Ilyeon Pharmaceutical (이연제약)coreMOU signed October 2022 for joint development of complex hemostatic medical device. Matrix-type product received MFDS Class 4 approval July 2025. Combines T&R Biofab's ECM technology with Ilyeon Pharmaceutical's thrombin for a differentiated hemostatic product targeting the 2,700B KRW domestic market.
- NeopharmminorSupply contract signed September 2022 for wound covering materials (창상피복재) distribution.
- Johnson & Johnson Mentor Worldwide LLCcoreStrategic joint research agreement signed June 2022 for the development of 3D bioprinting scaffold technology for tissue reconstruction. Builds on an earlier joint research agreement with Johnson & Johnson Medical Ethicon from February 2020.
- MegaGen Implant (메가젠임플란트)minorDistribution of dental 3D printing product (absorbable membrane) through MegaGen Implant since 2019.
- B.Braun Korea (비브라운코리아)coreSupply and distribution agreement for TnR CranioFacial Implants (CFI). Launched April 2021. Used in 67 hospitals by June 2022. FDA submission for US market filed June 2025. B.Braun is a leading global medical solutions company.
- Academia Japan Inc. (Japan iPSC licensing)coreLicense agreement signed August 2020 for iPSC-based cardiomyocyte production technology. T&R Biofab acquired sales rights for commercial cell products. Enables proprietary cell therapy development using induced pluripotent stem cells.
- Kyungpook National University Hospital & Chilgok Kyungpook National University Hospital (경북대학교병원, 칠곡경북대학교병원)coreContract from April 2020 to December 2021 to collect clinical information and biological samples (skin, blood, adipose tissue) from 50 donors under 40 years old, meeting US FDA standards. Successfully completed, enabling T&R Biofab's commercial cell bank. Both IRB-approved and FDA-compliant.
- Merck (밀리포어시그마)minorGlobal distribution agreement for bioink products through Merck's life science distribution network, enabling international reach for T&R Biofab's deCelluid bioink product.
- CHA-Biotech (차바이오텍)minorCollaboration signed June 2018 for development of cell therapy products combining CHA's stem cell technology with T&R Biofab's 3D bioprinting platform.
- Busan National University Hospital (부산대학교병원)minorMOU signed April 2018 for commercialization of enhanced blood vessel stem cell therapy products combining hospital's cell therapy research with T&R Biofab's 3D bioprinting technology.
- POSTECH (Pohang University of Science and Technology) / 포항공과대학교 산학협력단coreOpen Innovation Center opened at POSTECH in June 2016. Patent transfer agreement signed September 2014. Ongoing joint research producing publications in Nature Communications (2019), Advanced Materials (2021), and Small (2020). POSTECH is a key academic partner for T&R Biofab's R&D capabilities.
- Seoul St. Mary's Hospital (서울성모병원)core3D Printing-based Clinical Center opened March 2016. First clinical application of scaffolds in September 2014. Joint research on 3D bioprinted liver organoids (Advanced Materials 2021). Primary clinical partner for medical device testing and validation.
Scale indicators11 records
Recent moves8 records
Expansion highlights3 records
T&R Biofab competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights7 records
Customer concentration
T&R Biofab social profiles
Digital presenceT&R Biofab compliance and trust
Trust signalCompliance6 records
T&R Biofab financial estimates
Financial estimateRevenue estimate
Valuation estimate
T&R Biofab leadership team
Management profileNumber of profiles
Profiles3 records
T&R Biofab subsidiaries and ownership
Company hierarchySubsidiaries1 record
T&R Biofab funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
T&R Biofab M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about T&R Biofab
What does T&R Biofab do?
T&R Biofab develops and manufactures 3D-bioprinted medical devices, biomaterials, and bioprinting platforms for regenerative medicine. Its portfolio includes patient-specific craniofacial implants (TnR PSI Plus, CFI, Mesh, Nasal Mesh), VdECM-based biosurgical wound-care solutions (Reproderm-gel and the ADM product line), the 3DX bioprinting system, and the deCelluid bioink, sold to hospitals, medical-device distributors, and research institutions.
Is T&R Biofab a public or private company?
T&R Biofab is a public company. It is classified as public and is currently operating.
When was T&R Biofab founded?
T&R Biofab was founded in 2013. It employs 51 to 100 people.
Where is T&R Biofab based?
T&R Biofab is headquartered in Siheungodong, South Korea, in the Asia region.
How does T&R Biofab make money?
Six revenue lines are on record. 3D-Printed Medical Devices are the primary driver. The others are 3D Bioprinter and Platform Sales (3DX Printer), biosurgical Solutions (Wound Care & Hemostats), functional Cosmeceuticals & OEM, hiPSC-Based Cell Therapy & Cell Banking and bioink and Biomaterial Reagents.
Does T&R Biofab have an API?
No public API is recorded for T&R Biofab.
What industry is T&R Biofab in?
T&R Biofab's product category is 3D Bioprinting & Regenerative Medicine Medical Devices. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication, with a secondary code of IMAAAAAG, Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware). Its NAICS code is 3391 and its SIC code is 3841.